OFFICIAL ENTIS POSITION STATEMENT: Paracetamol (acetaminophen, APAP) use in pregnancy

A recent “consensus statement” review article published in Nature Reviews Endocrinology concluded that there is a growing body of evidence supporting the hypothesis that in utero exposure to paracetamol (or acetaminophen, APAP) impacts fetal development. This paper has been widely cited by national media organisations, some of which reported the findings in an alarming manner. ENTIS holds the position that the evidence supporting an increased risk of untoward fetal effects and childhood neurodevelopment, including ASD & ADHD following in utero exposure to paracetamol (acetaminophen) is weak, inconsistent and to a large extent fundamentally flawed. ENTIS holds the position that paracetamol (acetaminophen) is the first-choice analgesic and antipyretic for pregnant women, but, as for any medication, should only be used when clearly indicated at the lowest dose and for the shortest possible duration. Read the complete position statement here.